COSENTYX DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In October 2023, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. Food and Drug Administration (FDA) had approved Cosentyx (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only U.S. FDA-approved completely human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine thought to be involved in the inflammation of HS.
• In October 2023, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. FDA had approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA)
• In December 2021, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. FDA had approved Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older, and active psoriatic arthritis (PsA) in patients two years or older